Q3 FY26 results: standalone PAT Rs 1,121 Mn, 9M revenue up 11% on CRDMO growth

Revenue DeclineExceptional ItemEbitda Margin ExpansionResults View source PDF Explain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹608.95

prior close

₹598.10

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.3%+4.6% vs market

Pharmaceuticals & Biotechnology peers, median of 162sector · industry level-0.5%+4.8% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Midcap 150 and 4.8 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+2.2

15m

+3.3

30m

+3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3-0.3+4.6-0.5+4.8

Next day

+6.7-0.3+7.1-1.2+7.9

+10.8+1.2+9.6+0.4+10.4

+11.0+1.6+9.4+1.0+10.0

+13.4+1.6+11.8+0.9+12.5

+15.5+1.1+14.4+0.0+15.5

+12.9-0.1+13.0-1.4+14.2

15d

+15.8+0.4+15.4-2.9+18.7

+9.1-3.1+12.1-5.1+14.1

+9.0-8.7+17.7-7.2+16.2

+25.5+0.8+24.7+0.4+25.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals & Biotechnology peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anthem Biosciences reported Q3 FY26 standalone revenue of Rs 4,165.75 Mn, down about 16% YoY from Rs 4,982.62 Mn, though 9M revenue rose about 11% to Rs 15,068.12 Mn. Standalone Q3 PAT was Rs 1,121.25 Mn versus Rs 1,279.93 Mn, while 9M PAT grew about 20% to Rs 4,588.98 Mn. Consolidated 9M revenue was Rs 15,133.89 Mn and 9M PAT Rs 4,020.34 Mn. Board allotted 1,03,800 ESOP shares at Rs 100.75. An exceptional provision of Rs 249.84 Mn (standalone) was booked for new Labour Codes. Statutory auditor K.P. Rao and Co. issued an unqualified review.

Likely market impact

Mixed quarter: 9M growth strong on CRDMO, but Q3 revenue dipped. Labour Code exceptional hit. Mild ESOP dilution.